The ACHIEVE-4 trial evaluated the efficacy and safety of orforglipron in adults with type 2 diabetes and obesity or overweight with increased risk of cardiovascular events.

The expanded labeling reinforces Caldolor’s role in multimodal analgesia, offering a non-opioid option for postoperative pain in patients as young as 3 months.

Improvement in median overall survival of 2.9 months and decrease in risk for death reported with elraglusib/GnP vs GnP alone.

One in 4 US adults report using artificial intelligence tools or chatbots for physical or mental health information, according to new research released today from the West Health-Gallup Center on ...

HealthDay News — Recommendations for the diagnosis and management of severe acquired aplastic anemia are presented in a clinical practice guideline issued by the American Society of Hematology and ...

30-day adjusted risk ratios for short- versus long-course antibiotic therapy not significant for mortality, readmission, urgent visit ...

Approval was supported by the phase 3 LANDI-PED study, which demonstrated significant heart rate reduction and conversion to normal sinus rhythm in pediatric patients.

Among those with XDR isolates with species information, 65.9 and 34.1 percent were Shigella sonnei and Shigella flexneri ...

The unit-dose amlodipine powder for oral solution provides a stable, preservative-free alternative for patients who struggle with traditional tablet formulations.

Following favorable phase 1 data showing significant reductions in HBV DNA and RNA, the FDA has fast tracked pevifoscorvir sodium for chronic HBV infection.

Delgocitinib cream was shown to be effective and well-tolerated in adolescents with chronic hand eczema in the phase 3 DELTA TEEN clinical trial.

Food supplementation not associated with improvement in primary clinical outcomes, but researcher notes improvement in health-related quality of life.